Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial PharmaphorumNovartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.CardiovascularRead full story pharminent September 7, 2026 (Last updated: September 9, 2026) Pharmaphorum Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial. Cardiovascular Read full story Post navigation Previous: FDA approves AstraZeneca’s Etcamah combo for advanced breast cancerNext: UK’s Claret Capital raises 575m for European biotechs Related Stories Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026 Clinical Data Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again pharminent September 3, 2026